Navigation Links
Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference
Date:12/5/2007

WESTMINSTER, Colo., Dec. 5 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that Paul L. Berns, President and CEO, will participate on the "Better Drugs & Novel Approaches To Cancer Therapy" panel at the 2007 RBC Capital Markets Healthcare Conference in New York.

The panel presentation will take place at 1:30 p.m. (Eastern) on December 13, 2007. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through December 28, 2007.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkins Lymphoma (NHL). For additional information, please visit the Company's website at http://www.allos.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.


'/>"/>
SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
2. Allos Therapeutics Reports Third Quarter 2007 Financial Results
3. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
4. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
5. Prime Therapeutics Receives TIPPS Certification
6. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
7. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... ... of Sovaldi, which made headlines mostly for its cost despite its potential to ... moral questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have created ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... This Mother’s ... for women everywhere. The 17th annual National Women’s Health Week takes place ... on Women’s Health are combining forces to empower women to make their health a ...
(Date:5/6/2016)... W.V. (PRWEB) , ... May 06, 2016 , ... “ ... WestBow Press) shares accounts of dying patients who have allowed those holding vigil to ... E. Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain insight ...
(Date:5/5/2016)... , ... May 05, 2016 , ... TransWipe Volume 3 ... Pro X. Drag and drop a TransWipe preset between two video clips to instantly ... corner wipes to colored panels with customizable color and orientation options. TransWipe Volume 3 ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... overall select performance in the industry’s gold standard KLAS Performance Report, ... Epic Consulting report assessed organizations that specialize in consulting services for electronic health ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 2016 BioNovus Innovations LLC and the ... Medical Innovation (IAMI) today announced a new partnership ... medical devices. An agreement between the ... license, develop and commercialize medical innovations advanced through ... partnership represents a significant advance in our ability ...
(Date:5/3/2016)... May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, ... - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... BROOMALL, Pa. , May 3, 2016 ... Attorney Jack Whelan and Delaware County ... NARCAN® (naloxone HCI) Nasal Spray in all ACME ... the U.S. Centers for Disease Control and Prevention (CDC), naloxone has ... 2014, when police officers in Delaware County ...
Breaking Medicine Technology: